$0.46
(Market cap
$8 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-26.9
-
Face value
--
-
Shares outstanding
1,461,449
7 Years Aggregate
CFO
$-50.09 Mln
EBITDA
$-68.75 Mln
Net Profit
$-69.17 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cns Pharmaceuticals Inc (CNSP)
| 13.9 | 23.3 | 9.9 | -3.5 | -95.1 | -91.7 | -- |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Cns Pharmaceuticals Inc (CNSP)
| -92.7 | -99.8 | -47.1 | -88.6 | -60.6 | -54.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cns Pharmaceuticals Inc (CNSP)
|
6.0 | 8.1 | 0.0 | -16.7 | -- | -147 | -- | 0.4 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 147.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Cns Pharmaceuticals Inc (CNSP)
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical... trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas. Read more
-
CEO, President & Director
Mr. John Michael Climaco Esq., J.D.
-
CEO, President & Director
Mr. John Michael Climaco Esq., J.D.
-
Headquarters
Houston, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cns Pharmaceuticals Inc (CNSP)
What is the current share price of Cns Pharmaceuticals Inc (CNSP) Today?
The share price of Cns Pharmaceuticals Inc (CNSP) is $5.98 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Cns Pharmaceuticals Inc (CNSP) has given a return of -95.12% in the last 3 years.
What is the current PB & PE ratio of Cns Pharmaceuticals Inc (CNSP)?
Since, TTM earnings of Cns Pharmaceuticals Inc (CNSP) is negative, P/E ratio is not available.
The P/B ratio of Cns Pharmaceuticals Inc (CNSP) is 0.44 times as on 28-Aug-2026, a 92 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.15 |
0.51 |
2024 |
0.00 |
0.00 |
2023 |
0.00 |
0.00 |
2022 |
-- |
-- |
2021 |
-- |
-- |
What is the 52 Week High and Low of Cns Pharmaceuticals Inc (CNSP)?
The 52-week high and low of Cns Pharmaceuticals Inc (CNSP) are Rs 10.59 and Rs 1.90 as of 01-Sep-2026.
What is the market cap of Cns Pharmaceuticals Inc (CNSP)?
Cns Pharmaceuticals Inc (CNSP) has a market capitalisation of $ 8 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cns Pharmaceuticals Inc (CNSP)?
Before investing in Cns Pharmaceuticals Inc (CNSP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.